Literature DB >> 14713381

The emergence of type 2 diabetes in childhood.

Sarah Ehtisham1, Timothy G Barrett.   

Abstract

Type 1 diabetes (with predominant insulin deficiency) was until recently assumed to be the diagnosis of almost all children presenting with glucose intolerance. This requires insulin treatment via subcutaneous injections, and most patients develop microvascular and macrovascular complications in adulthood. Advances in genetics in the 1990s identified a group of genetic disorders of pancreatic beta-cell function (maturity-onset diabetes of the young) for which the outlook is better than type 1, genetic testing is available, and oral medication is the preferred treatment. In 2000, the first cases of type 2 diabetes (predominant insulin resistance) were reported in UK children, reflecting a trend seen in North America over the last 20 years. Affected children are usually overweight or obese, often female, pubertal, predominantly of ethnic minority (South Asian) origin and have a family history of type 2 diabetes. The diagnosis is aided by demonstration of insulin resistance, and may include measurement of fasting insulin and C-peptide, markers of the metabolic syndrome (fasting lipids, sex hormone binding globulin) and absence of autoantibodies against beta-cell components (e.g. glutamic acid decarboxylase). Management is aimed towards weight stabilization in the growing child, education on healthy lifestyles and the treatment of hyperglycaemia with both insulin and insulin-sensitizing agents. The underlying cause of type 2 diabetes in children is likely to be related to the epidemic of childhood obesity. There is emerging evidence of an appalling outlook for these young people in terms of miscarriages and microvascular and cardiovascular complications, which are likely to present an enormous economic and health services burden over the next 20 years.

Entities:  

Mesh:

Year:  2004        PMID: 14713381     DOI: 10.1258/000456304322664654

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  8 in total

1.  Moving our children to health. Active play every day.

Authors:  Maureen F Kennedy
Journal:  Can Fam Physician       Date:  2004-04       Impact factor: 3.275

2.  Changing perspectives in diabetes: their impact on its classification.

Authors:  T J Wilkin
Journal:  Diabetologia       Date:  2007-04-25       Impact factor: 10.122

3.  Liver biopsy in a district general hospital: changes over two decades.

Authors:  Wing-Kin Syn; Caroline Bruckner-Holt; Adam Farmer; Sarah Howdle; Jeffrey Bateman
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

4.  Adiponectin moderates the relationship between adiposity and leptin in adolescents regardless of gender or race.

Authors:  Vanessa Bundy; Maribeth Johnson; Bernard Gutin; Haidong Zhu; Inger Stallmann-Jorgensen; Yanbin Dong
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

5.  Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors.

Authors:  Wing-Kin Syn; Peter Nightingale; Jeffrey M Bateman
Journal:  Hepatol Int       Date:  2008-02-28       Impact factor: 6.047

6.  Age before stage: insulin resistance rises before the onset of puberty: a 9-year longitudinal study (EarlyBird 26).

Authors:  Alison N Jeffery; Brad S Metcalf; Joanne Hosking; Adam J Streeter; Linda D Voss; Terence J Wilkin
Journal:  Diabetes Care       Date:  2012-01-25       Impact factor: 19.112

7.  Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0-29 years in West Yorkshire, U.K., 1991-2006.

Authors:  Katie L Harron; Richard G Feltbower; Patricia A McKinney; H Jonathan Bodansky; Fiona M Campbell; Roger C Parslow
Journal:  Diabetes Care       Date:  2011-01-28       Impact factor: 19.112

8.  Can the Molar Insulin: C-Peptide Ratio Be Used to Predict Hyperinsulinaemia?

Authors:  Lynda Guildford; Catherine Crofts; Jun Lu
Journal:  Biomedicines       Date:  2020-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.